OUR PORTFOLIO

Our portfolio includes grants and mission-related investments supporting Alzheimer’s drugs in development, biomarkers, prevention programs, and other projects designed to build the capacity of the field. You can explore the programs we have supported using the filter and “Search Database” options in the sidebar.

All Filters

Clear
Clear
Clear
Clear
Clear
Clear
Clear
Organization: Johns Hopkins University

9 Projects | 6 Researchers | $1,965,819 Invested

2024

Johns Hopkins University

Philip Wong, PhD

Develop a diagnostic biomarker for frontotemporal dementia.

  • Funding Amount: $640,000
  • Organization Type: Academic/Nonprofit
  • Program: Biomarkers
  • Target: TDP-43
  • Status: Active

2024

Johns Hopkins University

Jeffrey Rothstein, MD, PhD

Mitigating TDP-43 loss of function and disease initiation in FTD thru repair of the Nuclear Pore and CHMP7/ESCRT3 dysfunction.

  • Funding Amount: $269,967
  • Organization Type: Academic/Nonprofit
  • Program: Drug Discovery
  • Target: TDP-43
  • Status: Active

2021

Johns Hopkins University

Paul Worley, MD

Preserving NPTX2 and Memory in Alzheimer's Disease

  • Funding Amount: $150,000
  • Organization Type: Academic/Nonprofit
  • Program: Drug Discovery
  • Target: Synaptic Activity and Neurotransmitters
  • Status: Closed

2018

Johns Hopkins University

Paul Worley, MD

Resilience Biomarker NPTX2 and AD Progression

  • Funding Amount: $160,000
  • Organization Type: Academic/Nonprofit
  • Program: Biomarkers
  • Status: Closed

2017

Johns Hopkins University

Valina Dawson, PhD

Parthanatos Inhibitors for Neuroprotection

  • Funding Amount: $167,858
  • Organization Type: Academic/Nonprofit
  • Program: Drug Discovery
  • Target: Neuronal Degeneration
  • Status: Closed

2013

Johns Hopkins University

Jeffrey Rothstein, MD, PhD

Biomarker assay development to accompany antisense oligonucleotide therapeutic for mutant C9orf72-positive FTD patients

  • Funding Amount: $150,168
  • Organization Type: Academic/Nonprofit
  • Program: Biomarkers
  • Target: Other
  • Status: Closed

2012

Johns Hopkins University

Jeffrey Rothstein, MD, PhD

Development of Antisense therapy and Therapeutic biomarker for C9orf72 FTD/ALS mutation patients

  • Funding Amount: $125,856
  • Organization Type: Academic/Nonprofit
  • Program: Drug Discovery
  • Target: Other
  • Status: Closed

2012

Johns Hopkins University

Andrew Horti, PhD

Cannabinoid CB2 radioligands for PET imaging of neuroinflammation in Alzheimer's disease

  • Funding Amount: $149,970
  • Organization Type: Academic/Nonprofit
  • Program: Biomarkers
  • Status: Closed

2010

Johns Hopkins University

Michelle Carlson, PhD

Effects of a Social Health Promotion Program on Neurocognitive Function: Experience Corps

  • Funding Amount: $152,000
  • Organization Type: Academic/Nonprofit
  • Program: Prevention
  • Status: Closed